Novartis’ remibrutinib cuts MS relapses, but by less than analysts expected
Novartis' remibrutinib reduced MS relapses by 35.2% and 31.2% vs. teriflunomide, below analyst expectations of 45-60%. Roche's competing drug fenebrutinib showed a 55% reduction. Novartis highlights remibrutinib's potential, with analysts estimating peak sales over $4B if approved. Safety concerns remain for both drugs.
How this was made
The 30-second read
Why it matters
The trial results are below consensus, likely prompting a short‑term price dip for Novartis while keeping long‑term pipeline prospects alive.
Market read
First‑report of pivotal MS trial data for a major biotech; material for short‑term trading and sector sentiment.
What to watch
Potential for remibrutinib in other autoimmune indications could offset the MS shortfall.
Background
The data were presented at a Toronto medical conference and represent the first detailed disclosure beyond a prior summary.
Ticker impact
Novartis' oral MS drug remibrutinib reduced relapse rates by 35.2% and 31.2% versus teriflunomide, missing analyst expectations of 45‑60% reduction.
likely downside as investors price in weaker-than-expected trial results
First‑report of Phase III data that falls short of consensus forecasts, a material catalyst for a large‑cap biotech.
Market effects
May temper enthusiasm for the BTK inhibitor class in multiple sclerosis and could slow pipeline momentum.
Impacts North American and European MS treatment markets where Novartis has significant sales.
Adds a data point for biotech investors tracking late‑stage neurology trials.
Counterpoint
If safety profile remains clean, investors may view the modest efficacy as acceptable given unmet need, supporting a rebound.
Key entities
- CompanyNovartis
Swiss pharma company developing remibrutinib for multiple sclerosis.
